About | Free Trial

Last Update

2012-04-11T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Background Information

Employment History

Director

Portola Pharmaceuticals , Inc.

Adjunct Assistant Clinical Professor of Medicine, Cardiology Division

University of California , San Francisco

Senior Director, Clinical Development

Portola Pharmaceuticals , Inc.

Vice President, Clinical Research

Nile Therapeutics , Inc.

Director, Clinical Research and Development

CV Therapeutics , Inc.

Researcher

J. David Gladstone Institute of Cardiovascular Disease at the University of California at San Francisco

Affiliations

Fellow
American College of Cardiology

Education

M.D.

Albert Einstein College

M.D.

Albert Einstein College of Medicine

Web References (71 Total References)


Zacks Small Cap Research - NLTX -Nile's Cenderitide Clears Phase 1

scr.zacks.com [cached]

On March 26, 2012, Dr. Hsiao D. Lieu, MD, FACC, Nile Therapeutics' (OTC Markets:NLTX) Vice President of Clinical Research, presented the results from the company's phase 1 safety and pharmacokinetic / pharmacodynamic (PK/PD) clinical trial with cenderitide at the 61th annual Scientific Session of the American College of Cardiology (ACC) meeting held in Chicago, IL. The poster presentation ( board #628) was titled, "Initial Experience with Subcutaneous Infusion of Cenderitide in Patients with Chronic Heart Failure."


Nile Therapeutics, Inc.

www.nilethera.com [cached]

February 25, 2008 - Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics > Read


Nile Therapeutics, Inc.

www.nilethera.com [cached]

Hsiao Dee Lieu, M.D., F.A.C.C. Vice President of Clinical Research

Dr. Lieu has over 13 years of experience in the biopharmaceutical/biotech industry including academic medicine (cardiology), molecular cardiology research, translational and clinical drug development including execution of large multinational Phase III clinical trials and responsibility for interactions with regulatory authorities and key opinion leaders in the U.S., Canada, and Europe. Prior to joining Nile, Dr. Lieu served as the Director of Clinical Development for Portola Pharmaceuticals, Inc. In this role, Dr. Lieu was responsible for the overall clinical development plan and execution for early- to late-stage intravenous and oral molecules including a large ADP antagonist program in acute coronary syndrome. Before joining Portola, Dr. Lieu served as the Director of Clinical Research and Development at CV Therapeutics, Inc. In this role, Dr. Lieu led the clinical development program for regadenoson, which included two successful large multinational Phase III trials. Dr. Lieu also worked as a researcher at the J. David Gladstone Institute of Cardiovascular Disease at the University of California at San Francisco (UCSF) conducting molecular cardiology research in gene manipulation and induction of cardiomyopathy and atherosclerosis regression. Dr. Lieu currently serves as Assistant Clinical Professor of Medicine, Cardiology Division at UCSF. Dr. Lieu completed his clinical cardiology fellowship at UCSF and his residency in internal medicine at Columbia University. He received his M.D. from the Albert Einstein College of Medicine with distinction in molecular biology research, and his B.A. from New York University.


Nile Therapeutics, Inc.

www.nilethera.com [cached]

Hsiao Dee Lieu, M.D., F.A.C.C. Vice President of Clinical Research

Dr. Lieu has over 13 years of experience in the biopharmaceutical/biotech industry including academic medicine (cardiology), molecular cardiology research, translational and clinical drug development including execution of large multinational Phase III clinical trials and responsibility for interactions with regulatory authorities and key opinion leaders in the U.S., Canada, and Europe. Prior to joining Nile, Dr. Lieu served as the Director of Clinical Development for Portola Pharmaceuticals, Inc. In this role, Dr. Lieu was responsible for the overall clinical development plan and execution for early- to late-stage intravenous and oral molecules including a large ADP antagonist program in acute coronary syndrome. Before joining Portola, Dr. Lieu served as the Director of Clinical Research and Development at CV Therapeutics, Inc. In this role, Dr. Lieu led the clinical development program for regadenoson, which included two successful large multinational Phase III trials. Dr. Lieu also worked as a researcher at the J. David Gladstone Institute of Cardiovascular Disease at the University of California at San Francisco (UCSF) conducting molecular cardiology research in gene manipulation and induction of cardiomyopathy and atherosclerosis regression. Dr. Lieu currently serves as Assistant Clinical Professor of Medicine, Cardiology Division at UCSF. Dr. Lieu completed his clinical cardiology fellowship at UCSF and his residency in internal medicine at Columbia University. He received his M.D. from the Albert Einstein College of Medicine with distinction in molecular biology research, and his B.A. from New York University.


This is the first time we ...

www.nilethera.com [cached]

This is the first time we have shown it is feasible to dose cenderitide subcutaneously and to target desirable plasma levels," said Hsiao Lieu, MD, Executive Vice President of Clinical Research at Nile.

Similar Profiles

Other People with this Name

Other people with the name Lieu

Jennifer Lieu
Arts Commission

Fiona Lieu
LAVINA Dental Lab Co. Ltd

Ted Lieu
Ted Lieu

Annie Lieu
Waitex

Nancy Lieu
Mitchell Partners

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory